drugset / Trial / NCT00708591
Study of Rapamycin Plus Ketoconazole in Advanced Cancers
NaSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose, observed toxicities, and dose limiting toxicities, and antitumor response of rapamycin plus ketoconazole in patients with advanced cancers.
Timeline
- Start
- 2004-10
- Primary completion
- 2008-12
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketoconazole | Small molecule | 200 mg | — |
| Subject | Sirolimus | Small molecule | — | Oral |